Lyumjev Solution for Injection (3ml Each) contains Insulin Lispro at a concentration of 100 units per milliliter and is indicated for the management of diabetes mellitus requiring rapid-acting insulin therapy. Insulin Lispro is a recombinant human insulin analog designed to provide rapid onset and short duration of action, closely mimicking physiological prandial insulin secretion. Lyumjev facilitates improved postprandial glucose control by promoting cellular uptake of glucose, thereby reducing hyperglycemia in patients with type 1 and type 2 diabetes. The solution is administered subcutaneously prior to meals to optimize glycemic control and can be used in combination with longer-acting insulin formulations or oral antidiabetic agents as part of a comprehensive diabetes management plan. The pharmacokinetic profile of Lyumjev allows for flexibility in dosing and timing relative to food intake. Patients should be monitored regularly for blood glucose levels to adjust dosage and prevent hypoglycemia, the most common adverse effect. Proper injection technique and site rotation are essential to minimize local reactions. Lyumjev should be stored under recommended conditions to maintain potency. This medication is contraindicated in patients with hypersensitivity to insulin lispro or any excipients and requires careful consideration in individuals with renal or hepatic impairment.